Get started
Author

Lysian Cartier

Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression
2011 · Nadia Malkoun, Cyrus Chargari, et al. · Journal of Neuro-Oncology · 50
Dosimetric study of volumetric arc modulation with RapidArc and intensity-modulated radiotherapy in patients with cervical cancer and comparison with 3-dimensional conformal technique for definitive radiotherapy in patients with cervical cancer
2015 · Jean-Baptiste Guy, Alexander T. Falk, et al. · Medical dosimetry · 39
Radiothérapie de la chaîne mammaire interne dans les cancers du sein : état des lieux
2010 · P. Auberdiac, L. Cartier, et al. · Cancer/Radiothérapie · 10
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol
2023 · Maximilien Rogé, Yoann Pointreau, et al. · Clinical and Translational Radiation Oncology · 9
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 · Stephane Gilles Guerif, Igor Latorzeff, et al. · Journal of Clinical Oncology · 9
Principes et traitements par chimiothérapie et radiothérapie des cancers bronchiques non à petites cellules
2009 · L. Cartier, P. Fournel · Encyclopédie médico-chirurgicale. Pneumologie · 8
Imagerie de contrôle de positionnement : quelle fréquence pour quel objectif ?
2012 · L. Cartier, M. Alfonsi, et al. · Cancer/Radiothérapie · 7
Radiothérapie des aires ganglionnaires sus- et sous-claviculaire dans les cancers du sein : état des lieux
2012 · P. Auberdiac, L. Cartier, et al. · Cancer/Radiothérapie · 7
Hormonoradiothérapie exclusive dans la prise en charge du cancer du sein de la personne âgée : cas clinique et revue de la littérature des schémas hypofractionnés
2011 · P. Auberdiac, C. Chargari, et al. · Cancer/Radiothérapie · 7
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial
2026 · Cécile Ortholan, Anne Aupérin, et al. · The Lancet Healthy Longevity · 6
PDF
Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020
2023 · Alexandre Bertucci, Lysian Cartier, et al. · Cancers · 5
PDF
ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.
2024 · Stephane Oudard, Pierre Combe, et al. · Journal of Clinical Oncology · 3
Radiothérapie du creux axillaire dans les cancers du sein : état des lieux
2012 · Pierre Auberdiac, Cyrus Chargari, et al. · Bulletin du Cancer · 3
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial
2026 · Hugo Corda, Audrey Blanc-Lapierre, et al. · Radiotherapy and Oncology · 2
Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Multicenter Randomized Phase II Trial Comparing Radiotherapy +/- 6 Months of Degarelix as a Salvage Treatment for Patients with Detectable PSA after Radical Prostatectomy
2019 · I. Latorzeff, S. Guerif, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma
2013 · Aurélie Robles, Antonin Levy, et al. · World Journal of Radiology · 2
PDF
Intérêt d’un traitement d’entretien prolongé par témozolomide dans la prise en charge des patients atteints d’un glioblastome
2011 · N. Malkoun, M.-J. Fotso, et al. · Cancer/Radiothérapie · 2
2467 Combining SBRT and durvalumab in hormone-sensitive prostate cancer with oligorecurrent metastases: a randomized phase II trial (POSTCARD GETUG P13)
2025 · Laure Hily, Maximilien Rogé, et al. · Radiotherapy and Oncology · 1
OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT
2023 · I. Latorzeff, S. Guerif, et al. · Radiotherapy and Oncology · 1
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET
2021 · Gwenaelle Gravis, Aurélie Autret, et al. · Clinical Genitourinary Cancer · 1
PDF
Imagerie par résonance magnétique et délinéation de la prostate en radiothérapie : expérience monocentrique et revue de la littérature
2011 · P. Auberdiac, C. Chargari, et al. · The French Journal of Urology · 1
Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer
2026 · Quentin Josset, Audrey Blanc-Lapierre, et al. · European Urology Oncology
51 Safety Profile of Darolutamide Combined With ADT and Radiotherapy in Node-Positive Prostate Cancer: Analysis From the GETUG-P17 ALADDIN Trial
2026 · Jean-Emmanuel Bibault, Stéphane Supiot, et al. · Radiotherapy and Oncology
2263 Early Toxicity of elective nodal RT for Oligorecurrent Pelvic/Paraaortic nodes in Prostate Cancer: a randomised phase 3 trial OLIGOPELVIS-2/GETUG P12.
2026 · Hugo Corda, Audrey Blanc-Lapierre, et al. · Radiotherapy and Oncology
Prise en charge du cancer de la prostate oligorécidivant après traitement local à but curatif, à l’ère des imageries métaboliques et de la radiothérapie stéréotaxique
2020 · R. Boissier, M. Nédelec, et al. · Progrès en Urologie - FMC
Works count: 36
Citation count: 175
H-index: 7
I10-index: 3
Year
Topic
Type